<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961142</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-006016-33</org_study_id>
    <nct_id>NCT00961142</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia</brief_title>
  <acronym>CD3/CD19 Haplo</acronym>
  <official_title>Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity&#xD;
      conditioning regimen with CD3/CD19 depleted grafts. This study enrolls patients with acute&#xD;
      leukemia in complete remission with an indication for allogeneic HCT but without a suitable&#xD;
      HLA-identical donor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 30, 2015</completion_date>
  <primary_completion_date type="Actual">December 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment related mortality after haploidentical HCT</measure>
    <time_frame>1 year after HCT</time_frame>
    <description>Cumulative Incidence of treatment related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1, 2 and 5 years after inclusion</time_frame>
    <description>by Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Engraftment</measure>
    <time_frame>One year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Toxicity</measure>
    <time_frame>One year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Disease Free Survival</measure>
    <time_frame>1, 2 and 5 years after inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)</intervention_name>
    <description>Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either ALL or AML in CR with an indication for allogeneic HCT according&#xD;
             to the following criteria:&#xD;
&#xD;
          -  AML: high risk patients with one or more of the following risk factors:&#xD;
&#xD;
               -  FLT-3 mutation&#xD;
&#xD;
               -  Complex cytogenetics&#xD;
&#xD;
               -  abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p)&#xD;
&#xD;
               -  Late CR &gt; induction I&#xD;
&#xD;
               -  Age &gt;60&#xD;
&#xD;
               -  Patients in 2.CR&#xD;
&#xD;
               -  Secondary AML&#xD;
&#xD;
               -  Relapse after a preceding allogeneic HCT from an HLA-identical donor&#xD;
&#xD;
          -  ALL: high risk patients with one or more of the following risk factors:&#xD;
&#xD;
               -  Pro-B-ALL&#xD;
&#xD;
               -  Initial WBC &gt;30.000/µL&#xD;
&#xD;
               -  CR after day 46 after Induction II&#xD;
&#xD;
               -  Complex cytogenetics, t(9,22), t(4,11)&#xD;
&#xD;
               -  Early or mature T-ALL&#xD;
&#xD;
               -  Initially refractory patients with late CR&#xD;
&#xD;
               -  Rising MRD level&#xD;
&#xD;
               -  Patients in 2. CR&#xD;
&#xD;
               -  Relapse after a preceding allogeneic HCT from an HLA-identical donor&#xD;
&#xD;
               -  No HLA-identical donor (not more than 1 antigen mismatch (9/10-Match) or more&#xD;
                  than 2 allelic mismatches by high-resolution typing). Critical cases should be&#xD;
                  discussed with the PI.&#xD;
&#xD;
               -  Age &lt;=65, &gt;=18 years&#xD;
&#xD;
               -  Karnofsky Index &gt;60%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with &gt;5% blasts in BM at the time of transplantation&#xD;
&#xD;
          -  Less than 3 months after preceding HCT&#xD;
&#xD;
          -  CNS involvement with disease&#xD;
&#xD;
          -  History of neurologic impairment such as: seizures, severe peripheral neuropathy,&#xD;
             signs of leukoencephalopathy, CNS infection, multiple intrathecal chemotherapies, CNS&#xD;
             irradiation. In case of heavy pretreatment with irradiation or intrathecal&#xD;
             chemotherapy pretransplant CNS MRI and neurological consultation are mandatory&#xD;
&#xD;
          -  Fungal infections with radiological progression after receipt of amphotericin B or&#xD;
             active triazole for greater than 1 month.&#xD;
&#xD;
          -  Liver function abnormalities with bilirubin &gt;2 mg/dL and elevation of transaminases&#xD;
             higher 2x upper limit of normal.&#xD;
&#xD;
          -  Chronic active viral hepatitis&#xD;
&#xD;
          -  Ejection fraction &lt;40 % on echocardiography&#xD;
&#xD;
          -  Patients with &gt; grade II hypertension by CTC criteria&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min&#xD;
&#xD;
          -  Respiratory failure necessitating supplemental oxygen or DLCO &lt;30%&#xD;
&#xD;
          -  Allergy against murine antibodies&#xD;
&#xD;
          -  HIV-Infection&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential not employing an effective method of birth control during study treatment&#xD;
             and for at least 12 months thereafter. (Women of childbearing potential must have a&#xD;
             negative serum pregnancy test at study entry)&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,&#xD;
             congestive heart failure, myocardial infarction within 6 months prior to the study,&#xD;
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled&#xD;
             infection) which could compromise participation in the study&#xD;
&#xD;
          -  Patients with a history of psychiatric illness or condition which could interfere with&#xD;
             their ability to understand the requirements of the study (this includes&#xD;
             alcoholism/drug addiction)&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Enrollment in an other trial interfering with the endpoints of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang A. Bethge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University Hospital Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Dresden Medical Center</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marrow Transplantation, University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South West German Cancer Center, University of Tuebingen Medical Center</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wuerzburg Medical Center</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>http://www.onkologie-tuebingen.de/ifa0.htm</url>
    <description>Homepage BMT-Study Group Tuebingen</description>
  </link>
  <reference>
    <citation>Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.</citation>
    <PMID>17869547</PMID>
  </reference>
  <reference>
    <citation>Bethge WA, Haegele M, Faul C, Lang P, Schumm M, Bornhauser M, Handgretinger R, Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp Hematol. 2006 Dec;34(12):1746-52.</citation>
    <PMID>17157172</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Wolfgang Bethge</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Haploidentical Transplantation</keyword>
  <keyword>CD3/CD19 Depletion</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>Reduced Intensity Conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

